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Sir,
HIV-1 transmitted drug resistance (TDR) can impair the first-line
antiretroviral therapy response. Moreover, minority resistant vari-
ants (MRVs) can be a source of virological failure if they are present
before antiretroviral treatment. Nevertheless, few data are avail-
able for integrase strand transfer inhibitor (ISTI) TDR and studies
about the impact of integrase MRVs on virological failure are
contradictory. Furthermore, universal genotypic analysis of inte-
grase gene is not recommended before treatment initiation,
whereas the use of ISTI in clinical practice is largely increasing. In
this context, we have evaluated integrase majority resistant vari-
ants and MRVs in HAART-naive patients by Sanger sequencing and
ultradeep sequencing (UDS).
The population studied was composed of 92 treatment-naive
patients recently diagnosed with HIV-1 (2013–15): 70 MSM, 8 het-
erosexual patients (including one intravenous drug user), and
14 patients with unknown sexual orientation. Patients were fol-
lowed by the Department of Infectious Diseases and Internal
Medicine of Pitie´-Salpe^trie`re Hospital (Paris, France) and at the
University Hospital of Rome Tor Vergata (Rome, Italy). Information
was obtained from the existing electronic database and/or med-
ical record.
Integrase genotypic resistance analysis was performed in all
subjects from amino acids 53 to 288. Integrase Sanger sequencing
was conducted according to the Agence Nationale de Recherche
sur le SIDA et les he´patites virales (ANRS) consensus method as
previously described.1 The subtype determination was performed
using the Module HIV from SmartGeneVR (Zug, Switzerland) whose
methodology is based on BLAST. UDS was performed by using GS-
Junior platform according to manufacturer recommendations in
both clinical centres as previously described.2,3
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An amplicon variant analyser was used to analyse the UDS data,
with a detection threshold of MRV of 2% (forward and reverse).
Resistance was interpreted according to the last version of the
ANRS algorithm (www.hivfrenchresistance.org). The mutational
load was considered as the number of mutated copies/mL (prod-
uct of percentage of a mutation by viral load).
An average of 3464 reads per nucleotide position was ampli-
fied. Characteristics of patients are presented in Table 1. Viruses
of seven patients harboured majority resistant variants by
Sanger sequencing (five L74I and two E157Q mutations). In three
patients, viruses harboured MRVs detected by UDS only: two
R263K mutations (at a rate of 9.7% the mutational load is 7099
copies/mL, and at 13.5% the mutational load is 8345 copies/mL,
in the presence of a L74I mutation detected by both techniques)
and one E138K mutation (at 4.8%, 111 copies/mL). All these muta-
tions were retrieved/detected among MSM patients infected by a
subtype B virus.
None of the three classical ISTI signature resistance mutations
(at positions 143, 148 and 155) was retrieved. However, among
MSM treatment-naive patients, the prevalence of ISTI-associated
resistance mutations seems to be relatively high [10.0% by Sanger
(95% CI: 3.0%–17.0%) and 14.3% by UDS (95% CI: 6.1%–22.5%)].
Moreover, our results are consistent with what has been previously
shown by Sanger sequencing in the study on French patients diag-
nosed at the time of primary HIV-1 infection in which the E157Q
first generation ISTI mutation, was detected in 5 of 331 cases
(1.5%).4 Indeed, mutations detected by Sanger sequencing
(E157Q, L74I) are known to be mainly related to polymorphism in
databases, whereas mutations detected by UDS only (E138K,
R263K) are not.5,6 By querying a large Italian anonymous database
including 1307 integrase plasma Sanger sequences from HIV-1-
infected drug-naive patients, the R263K mutation was detected
only in five samples (0.4%), often as a mixture with the WT virus
R263R (D. Armenia, M. M. Santoro, D. Di Carlo, C. Gori, A. Bertoli, V.
Borghi, F. Ceccherini-Silberstein, C. Mussini, M. Andreoni, A. Antinori
and C. F. Perno, University of Rome Tor Vergata, unpublished
results). In vivo, the R263K mutation had been described in experi-
enced but also in ISTI-naive patients failing a dolutegravir once
daily regimen.7,8 This mutation had been described as a dolutegra-
vir resistance-associated mutation selected in cell culture with a
negative impact on viral fitness.9 This unfavourable impact might
explain why the R263K mutation was detected only by UDS as a
minority species in two patients in our study, whose viruses are not
phylogenetically related (genetic distance .8% between
sequences). Indeed, we can suppose that the low viral fitness
related to this mutation avoids the spread of these variants among
intra-patient quasispecies.
Furthermore, in our current dataset, one patient with R263K
harboured the TDR mutation K103N in the reverse transcriptase
gene. This patient was the only one who has initiated an integrase
inhibitor-based regimen (tenofovir, emtricitabine and raltegravir)
among patients with mutated viruses. Nevertheless, the virological
outcome was a success with a viral load ,50 copies/mL after
3, 6 and 12 months under this treatment. Indeed, in vitro, R263K
mutants obtained by side-directed mutagenesis were hypersensi-
tive to raltegravir (fold-change from 0.5 to 0.8).10
In conclusion, with the increased use of ISTI in clinical practice,
the presence of ISTI-associated resistance mutations in naive pa-
tients should be considered in the future, and our results suggest
that integrase pre-treatment genotypic analysis might be useful.
However, the impact of integrase MRVs should be further studied.
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Table 1. Characteristics of patients and global prevalence of ISTI muta-
tions; patients, n"92
Age (years), median (IQR) 36.1 (29.8–45.0)
Viral subtype B, % 58.2
HIV-1 RNA (log10 copies/mL), median (IQR) 4.9 (4.4–5.4)
CD4 cell count (cells/mm3), median (IQR) 461 (320–577)
Time since diagnosis (days), median (IQR) 12.0 (2.3–31.5)
Prevalence of ISTI mutations
with Sanger (95% CI)
n"7; 7.6% (2.2%–13.0%)
Prevalence of ISTI mutations
with UDS (95% CI)
n"10; 10.9% (4.5%–17.2%)
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Sir,
HIV-associated nephropathy (HIVAN) is still associated with high
mortality,1 and is usually a late complication of HIV chronic infec-
tion.2 Since 2010, a link has been strongly established between
APOL1 genetic variants and HIVAN, especially in the African
population.3
A middle-aged man from Ivory Coast was admitted to hospital
for a flu-like illness lasting for 1 month. He had already received
several antibiotic regimens and previous malaria and HIV tests
were negative. He had been on amlodipine/valsartan for many
years for hypertension and his plasma creatinine level 1 month be-
fore was 1.25 mg/dL (110lmol/L).
His weight had increased from 101 to 113 kg with pitting oe-
demas in the legs and frothy urine for 1 month. Diffuse small per-
ipheral lymphadenopathies were present. Clinical examination
was otherwise normal.
Biological assessment showed an acute kidney injury with indi-
cation for dialysis [serum creatinine 20.3 mg/dL (1781lmol/L),
blood urea nitrogen 40.7 mmol/L, potassium 5 mmol/L and carbon
dioxide 15 mmol/L] and a nephrotic syndrome with low serum al-
bumin (1.3 g/dL), high-level proteinuria (7 g per day) and a urinary
protein/creatinine ratio of 1.72. Ultrasound found normal-sized
hyperechogenic kidneys (12 cm each).
A renal biopsy showed typical HIVAN: one-third of the glomeruli
were sclerotic with all but one displaying a collapsing focal seg-
mental glomerulosclerosis (FSGS) with hypertrophic podocytes
(Figure 1a). The tubulointerstitial area revealed many cystic tubular
lesions associated with a moderate inflammatory infiltrate
(Figure 1b). Acute tubular necrosis lesions and a discrete patchy fi-
brosis were also present. The immunofluorescence study was
negative for IgA, IgG, IgM, C3, C1q and albumin.
The HIV test (ELISA) confirmed with a western blot (New
Lav Blot, Bio-Rad) returned positive. The p24 antigen was negative.
The initial CD4 count was 594 cells/mm3 (17%) and the
plasma HIV-1 RNA was 1.2 million (6.04 log) copies/mL. The pa-
tient tested negative for syphilis, hepatitis B and C and opportunis-
tic infections except for a cytomegalovirus (CMV) replication (3 log
DNA copies/mL). The HIV-1 strain was a CRF02_AG subtype with a
CCR5 tropism, and the genotyping assay displayed no resistance-
associated mutation.
ART was quickly initiated with raltegravir and etravirine with
addition of abacavir to the regimen when HLA B5701 returned
negative. Dialysis was continued for 2 weeks. Considering the
severity of renal failure and the nephrotic syndrome, the patient
received both angiotensin-converting enzyme (ACE) inhibitors
and corticosteroid therapy. Ten days after initiating treatment,
plasma creatinine decreased and stabilized at about 2.3 mg/dL
(200lmol/L); the protein/creatinine ratio also decreased to 0.46.
After 6 weeks of treatment, the HIV-1 load decreased to
449 copies/mL. The CD4 count increased to 1063 cells/mm3 (45%)
with a CD4/CD8 ratio of 1.18 and lymphadenopathy disappeared.
To confirm a recent HIV infection, we used both a supple-
mental western-blot assay (HIV Blot 2.2, MP Biomedicals,
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